Hook & thesis
Radian Group (RDN) is no longer just a mortgage insurer; management has pushed a fast, visible pivot into specialty insurance that the market has not fully priced. At $33.97 the stock trades at roughly 8x trailing earnings and about 1x book while offering a 3% dividend yield. Those multiples look cheap for a company with improving capital metrics, positive return on equity (12.2%), and an enterprise value/EBITDA of ~6.4x.
The trade: buy RDN today to capture valuation upside as investors digest the scale and margin profile of the newly enlarged specialty insurance business. This is a long trade that balances near-term yield with medium-term re-rating potential driven by the $1.7 billion Inigo acquisition and portfolio reshaping.
What Radian does and why the market should care
Radian Group provides mortgage insurance, risk management products, and real estate services. Historically the company aggregated and distributed mortgage credit risk for U.S. lenders and investors. Management has signaled and begun executing a strategic transformation - acquiring Inigo Limited for $1.7 billion on 09/18/2025 to accelerate a shift into global specialty insurance and signaling plans to divest certain mortgage, title, and real estate units by 2026.
Why that matters: specialty insurance typically carries more diverse underwriting opportunities, higher and more stable fee streams, and less correlation to U.S. mortgage cycles. If Radian can convert capital and expertise from mortgage distribution into specialty underwriting scale, the company should see higher risk-adjusted returns and a healthier multiple than a pure mortgage-insurer pigeonhole would imply.
Support for the thesis - the numbers
The valuation and capital metrics already provide a margin of safety. Market capitalization sits around $4.63 billion and enterprise value about $5.67 billion. Trailing EPS is $4.28 which yields a price-to-earnings near 8x. Price-to-book is roughly 0.97x and dividend yield is about 3%. Free cash flow last reported was $115.7 million, implying a price-to-free-cash-flow ratio near 40x on market cap alone, but enterprise multiples look more attractive: EV/EBITDA is 6.36x.
Operationally, Radian shows solid returns: return on equity ~12.2% and return on assets ~7.17%. The balance sheet is conservative for an insurer - debt to equity is only 0.22 and current/quick ratios are approximately 0.91, signaling liquid-oriented asset management. The company's 52-week range is $29.32 - $38.84, giving a realistic upside to the prior high while providing a clear technical reference for stop placement.
Valuation framing
| Metric | Value |
|---|---|
| Current price | $33.97 |
| Market cap | $4.63B |
| Enterprise value | $5.67B |
| P/E | ~8x |
| P/B | ~1x |
| EV/EBITDA | ~6.4x |
| Free cash flow | $115.7M |
| ROE | ~12.2% |
| D/E | ~0.22 |
Qualitatively, a mid-single-digit multiple expansion (from ~8x to low-teens P/E) would be sensible if the specialty insurance mix raises margins and stabilizes underwriting volatility. The market currently prices Radian near book with modest yield - attractive for a company that can demonstrate sustainable earnings growth from diversified underwriting and fee-based services.
Catalysts
- Integration and early results from the Inigo acquisition (announced 09/18/2025) - any evidence that Inigo's specialty underwriting lifts margins or generates cross-sell will be a direct re-rating catalyst.
- Announcements or progress on divesting mortgage, title, and real estate units by 2026 - clear perimeter-setting around the new specialty focus will reduce execution uncertainty.
- Better-than-expected FCF / buyback activity - given a conservative balance sheet, incremental capital returns would make the stock more attractive to yield-seeking investors.
- Product / tech wins such as the R3 Titlegenius collaboration (announced 11/13/2024) that lower operating costs or create new fee streams.
- Macro: stable or improving housing credit metrics that reduce mortgage-related loss volatility and free capital for specialty growth.
Trade plan - actionable rules
Entry price: 33.97
Target price: 38.50
Stop loss: 31.50
Horizon: long term (180 trading days) - I expect the market to slowly re-rate Radian as integration of Inigo completes and management shows progress divesting non-core assets. That process and subsequent multiple expansion should play out over a multi-month window rather than in days.
Rationale: Entry at $33.97 captures the stock inside its 52-week range with a favorable risk/reward - upside to $38.50 (near prior highs) and a stop beneath recent support and the low-$30s where downside starts to turn material. The stop at $31.50 limits losses if investor sentiment reverts to discounting mortgage-related tail risk. Adjust position size so that the difference between entry and stop matches your portfolio risk tolerance.
Technical context
Price sits above short-term averages (10- and 20-day SMAs around $33.12 and $33.02) and near its 50-day SMA (~$33.38). Momentum indicators are constructive: RSI ~58 and a positive MACD histogram. Short interest is moderate - recent settlement figures show about 6.5 million shares short as of 03/13/2026 with a days-to-cover near 4.55; this provides both liquidity and the potential for short-covering support on positive news.
Risks and counterarguments
Below are the principal risks that could derail this trade, followed by a direct counterargument to my bullish thesis.
- Execution risk on Inigo integration - acquisitions in insurance require precise underwriting and reserve management. If Radian misprices specialty risk or encounters unexpected claims development, earnings could disappoint and the re-rating evaporates.
- Divestiture delays or value destruction - planned divestments of mortgage, title, and real estate units are central to the repositioning thesis. Delays or weak exit prices would maintain conglomerate discount pressure.
- Macro credit shock - a deterioration in U.S. mortgage credit or a national housing correction would increase loss ratios in remaining mortgage exposure and could force higher reserves, compressing capital available for specialty growth.
- Capital allocation missteps - using excess capital to pursue aggressive, higher-volatility specialty lines without commensurate pricing could harm ROE and investor confidence.
- Regulatory / reserving risk - insurance businesses are sensitive to regulatory scrutiny and reserve adequacy. Reserve increases would hit earnings and book value directly.
Counterargument: Investors could reasonably argue Radian's pivot is cosmetic - that the company will retain mortgage-cycle correlated risk or that Inigo does not scale profitably. If specialty lines fail to deliver higher returns, then current multiples remain appropriate and the stock has limited upside. In that scenario, the dividend and buybacks may be the only value props and the re-rating thesis would be invalid.
Why this trade still makes sense
The counterargument is real, but the facts lean in favor of the conversion thesis: balance-sheet conservatism (D/E ~0.22), positive ROE (~12%), and an EV/EBITDA in the mid-single digits give management time to execute without immediate solvency pressure. The Inigo acquisition provides a clear, tangible step toward diversification rather than a vague strategic statement - the market typically rewards demonstrable earnings mix improvement.
What would change my mind
I would reduce conviction or exit the position if any of the following occur within the next 90-180 trading days:
- Management announces significant reserve additions tied to previously undisclosed mortgage losses or materially lower earnings guidance.
- Divestiture plans are abandoned or the company signals it will double down on mortgage exposure rather than specialty insurance.
- Integration metrics for Inigo show persistent margin erosion or loss-ratio deterioration beyond modeling assumptions.
- Macroeconomic indicators point to a rapid tightening in mortgage liquidity or a housing shock that materially raises credit losses.
Conclusion and stance
Radian at $33.97 presents a tradeable opportunity to own a transforming insurer with a healthy balance sheet, reasonable yield, and clear catalysts that could push the company out of its mortgage-insurer valuation bracket. The risk/reward defined by an entry at $33.97, target $38.50, and stop at $31.50 over a long-term (180 trading days) horizon is attractive for disciplined investors who size positions to the stop. Monitor integration progress for Inigo and progress on divestitures closely; those are the binary events that will validate the thesis or force a rethink.
Key metrics recap
- Price: $33.97
- Market cap: $4.63B
- P/E: ~8x
- P/B: ~1x
- Dividend yield: ~3%
- EV/EBITDA: ~6.4x
- Free cash flow: $115.7M
- ROE: ~12.2%
Trade the thesis with a plan, respect the stop, and treat integration milestones as event-driven opportunities to reassess sizing.